News
NLSPW
0.0069
-28.87%
-0.0028
Weekly Report: what happened at NLSPW last week (0505-0509)?
Weekly Report · 12h ago
Weekly Report: what happened at NLSPW last week (0428-0502)?
Weekly Report · 05/05 12:14
Weekly Report: what happened at NLSPW last week (0421-0425)?
Weekly Report · 04/28 12:27
Weekly Report: what happened at NLSPW last week (0414-0418)?
Weekly Report · 04/21 12:27
NLS Pharmaceutics Says Results From Study KO-943 Provides Evidence That Mazindol May Offer Non-Opioid Approach For Treatment Of Fentanyl Use Disorder
Benzinga · 04/15 13:06
NLS PHARMACEUTICS ANNOUNCES POSITIVE RESULTS FROM STUDY KO-943 DEMONSTRATING MAZINDOL REDUCES FENTANYL-INDUCED REWARD IN ANIMAL MODELS
Reuters · 04/15 13:00
Weekly Report: what happened at NLSPW last week (0407-0411)?
Weekly Report · 04/14 12:11
Weekly Report: what happened at NLSPW last week (0331-0404)?
Weekly Report · 04/07 12:11
Weekly Report: what happened at NLSPW last week (0324-0328)?
Weekly Report · 03/31 12:27
Weekly Report: what happened at NLSPW last week (0317-0321)?
Weekly Report · 03/24 12:11
Weekly Report: what happened at NLSPW last week (0310-0314)?
Weekly Report · 03/17 12:26
Weekly Report: what happened at NLSPW last week (0303-0307)?
Weekly Report · 03/10 12:27
Weekly Report: what happened at NLSPW last week (0224-0228)?
Weekly Report · 03/03 12:26
KADIMASTEM AND ITOLERANCE SUCCESSFULLY COMPLETE PRE-IND MEETING WITH THE FDA FOR ITS TYPE 1 DIABETES TREATMENT
Reuters · 02/25 14:05
Weekly Report: what happened at NLSPW last week (0217-0221)?
Weekly Report · 02/24 12:27
Weekly Report: what happened at NLSPW last week (0210-0214)?
Weekly Report · 02/17 12:23
NLS PHARMACEUTICS AND KADIMASTEM UNVEIL MULTI-TARGET APPROACH TO DIABETES, EXPANDING BEYOND GLP-1 THERAPIES
Reuters · 02/10 12:30
Weekly Report: what happened at NLSPW last week (0203-0207)?
Weekly Report · 02/10 12:13
Weekly Report: what happened at NLSPW last week (0127-0131)?
Weekly Report · 02/03 12:20
KADIMASTEM SHAREHOLDERS APPROVED THE MERGER WITH NLS PHARMACEUTICS
Reuters · 01/31 12:30
More
Webull provides a variety of real-time NLSPW stock news. You can receive the latest news about Nls Pharmaceutic through multiple platforms. This information may help you make smarter investment decisions.
About NLSPW
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.